SCHEMBL1266166

SCHEMBL1266166

Oc1cc(F)c(F)cc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.42
PPOX P50336 1/20 0.37
CA9 Q16790 2/20 0.36
CA3 P07451 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
CYP3A4 P08684 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
TSHR P16473 1/20 0.35
AKR1B1 P15121 1/20 0.34
PTPN1 P18031 2/20 0.33
ADRB2 P07550 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29547583 0.86 ALOX15 (0.40) ALOX15PPOXCA9CA3CA6
SCHEMBL366414 0.80 CA3 (0.40) ALOX15CA9CA3CA6CA5A
SCHEMBL31753632 0.80 CA3 (0.40) ALOX15CA9CA3CA6CA5A
SCHEMBL31207038 0.79 KDM1A (0.37) ALOX15CA9CA3CA6CA5A
SCHEMBL29768831 0.79 ALOX15 (0.37) ALOX15PPOXCA9CA3CA6
SCHEMBL5271664 0.79 KDM1A (0.36) ALOX15CA9CA3CA6CA5A
SCHEMBL5453603 0.79 CA9 (0.38) ALOX15PPOXCA9CA3CA6
SCHEMBL5987805 0.79 TSHR (0.40) ALOX15PPOXCA9ESR1ESR2
SCHEMBL1438611 0.79 KDM1A (0.37) ALOX15CA9CA3CA6CA5A
SCHEMBL15475662 0.79 ALOX15 (0.37) ALOX15PPOXCA9CA3CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116478199-A Bimetallic catalyst and preparation method thereof, and preparation method of high molecular weight olefin polymer 万华化学集团股份有限公司 2023-07-25 CN claimed
US-7902390-B2 carrier; organoaluminoxy compound treated with a compound having an electron withdrawing group and an active proton, ionic compound having at least one active proton; thermal stability, high catalyst activity ALBEMARLE CORPORATION (US) 2011-03-08 US claimed
US-20090270571-A1 CATALYST ACTIVATORS, PROCESSES FOR MAKING SAME, AND USE THEREOF IN CATALYSTS AND POLYMERIZATION OF OLEFINS ALBEMARLE CORPORATION (US) 2009-10-29 US claimed
EP-2041189-A2 CATALYST ACTIVATORS, PROCESSES FOR MAKING SAME, AND USE THEREOF IN CATALYSTS AND POLYMERIZATION OF OLEFINS Albermarle Corporation (US) 2009-04-01 EP claimed
US-20080300372-A1 Catalyst Activators, Processes for Making Same, and Use Thereof in Catalysts and Polymerization of Olefins ALBEMARLE CORPORATION 2008-12-04 US claimed
WO-2008011269-A2 CATALYST ACTIVATORS, PROCESSES FOR MAKING SAME, AND USE THEREOF IN CATALYSTS AND POLYMERIZATION OF OLEFINS ALBEMARLE CORPORATION (US) 2008-01-24 WO claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
US-6333388-B1 Aluminum compound-containing solid catalyst component, catalyst for olefin polymerization and method for producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-12-25 US claimed
US-6100213-A Aluminum compound-containing solid catalyst component, catalyst for olefin polymerization and method for producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-08-08 US claimed
US-12583856-B2 Inhibitors of protein kinase A BLUEPRINT MEDICINES CORPORATION (US) 2026-03-24 US disclosed
US-20260022100-A1 NAV1.8 INHIBITOR Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2026-01-22 US disclosed
EP-4561561-A2 SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR Septerna, Inc. (US) 2025-06-04 EP disclosed
EP-4545517-A1 NAV1.8 INHIBITOR Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-04-30 EP disclosed
EP-4541422-A2 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS Gilead Sciences, Inc. (US) 2025-04-23 EP disclosed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998002741-A9 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES 1998-05-22 WO disclosed
US-5716971-A FOR TREATMENT OF ANGINA PECTORIS AND HYPERTENSION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-10 US disclosed
WO-1998002741-A1 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-01-22 WO disclosed
EP-0623597-B1 Pyridine derivatives, with potassium channel opening activity TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-10-22 EP disclosed
EP-0623597-A1 Pyridine derivatives, with potassium channel opening activity Takeda Chemical Industries, Ltd. (JP) 1994-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022100-A1 NAV1.8 INHIBITOR SCN8A, SCN1B, SCN1A ALOX15 3632/4885PPOX 4689/4885CA9 493/4885
US-12583856-B2 Inhibitors of protein kinase A CSNK1A1, CSNK1A1L, CSNK1G1 ALOX15 4762/4885PPOX 3550/4885CA9 2944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.